XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue
 3 Months Ended
Mar. 31, 2021
Revenue from Contract with Customer [Abstract]  
Revenue RevenueOur revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with ASC Topic 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service.
The following table presents the approximate percentage of our net sales by market group:
Three Months Ended
March 31,
20212020
Biologics
39 %
28 %
Generics
 18 %
19 %
Pharma
24 %
29 %
Contract-Manufactured Products
19 %
24 %
100 %
100 %

The following table presents the approximate percentage of our net sales by product category:
Three Months Ended
March 31,
20212020
High-Value Product Components
52 %
43 %
High-Value Product Delivery Devices
5 %
5 %
Standard Packaging
24 %
28 %
Contract-Manufactured Products
19 %
24 %
100 %
100 %

The following table presents the approximate percentage of our net sales by geographic location:
Three Months Ended
March 31,
20212020
Americas
46 %
48 %
Europe, Middle East, Africa
44 %
44 %
Asia Pacific
10 %
8 %
100 %
100 %

Contract Assets and Liabilities

The following table summarizes our contract assets and liabilities, excluding contract assets included in accounts receivable, net:
($ in millions)
Contract assets, December 31, 2020$10.9 
Contract assets, March 31, 2021
12.5 
Change in contract assets - increase (decrease)$1.6 
Deferred income, December 31, 2020$(57.1)
Deferred income, March 31, 2021
(45.1)
Change in deferred income - decrease (increase)$12.0 

Starting in the third quarter of 2020, the Company entered into new capacity reservation agreements, which include the receipt of up-front cash. The decrease in the deferred income balance is primarily due to the revenue recognition associated with the capacity reservation agreements, which is to be recognized over the next 1 to 2 years.
During the three months ended March 31, 2021, $17.4 million of revenue was recognized that was included in deferred income at the beginning of the year.

The majority of the performance obligations within our contracts are satisfied within one year. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose® technology platform within a specific therapeutic area. As of March 31, 2021, there was $4.5 million of unearned income related to this payment, of which $0.9 million was included in other current liabilities and $3.6 million was included in other long-term liabilities. The unearned income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer.

Voluntary Recall

On January 24, 2019, we issued a voluntary recall of our Vial2Bag® product line due to reports of potential unpredictable or variable dosing under certain conditions. On October 21, 2020 we received market clearance from the Food and Drug Administration ("FDA") for our Vial2BagAdvancedTM 20mm Admixture Device and the product is back on the market.